CN-122017238-A - Application of PYGL as auxiliary diagnostic marker for acute liver failure related to hepatitis E

Abstract

The invention discloses an application of PYGL as an auxiliary diagnostic marker for acute liver failure related to hepatitis E, belonging to the technical field of biomedical detection. The invention can effectively distinguish the patients with acute liver failure (HEV-ALF) related to hepatitis E, acute Hepatitis E (AHE) and healthy control group (HCs) by detecting the expression level of PYGL in the serum of a subject. The results show that the serum PYGL expression level of HEV-ALF patients is obviously higher than that of acute hepatitis E patients and healthy control groups, has obvious correlation with the clinical outcome of hepatitis E-related acute liver failure patients, has obviously higher serum PYGL expression level than that of survival groups in dead groups, has correlation with the organ failure number of patients and can reflect the dynamic change of the patient's condition. Therefore, the serum PYGL can be used as an effective biomarker for assisting in diagnosing the hepatitis E-associated acute liver failure and performing prognosis evaluation on the hepatitis E-associated acute liver failure.

Inventors

• GU MENGMENG
• FENG SIYU
• WU JIAN
• WANG LUYU
• JI CHANGYI
• TAN JIAJUN

Assignees

• 苏州市立医院

Dates

Publication Date

20260512

Application Date

20260128

Claims (10)

1. 1. Use of serum glycogen phosphorylase L as a biomarker for aiding diagnosis and/or prognosis of acute liver failure associated with hepatitis e.
2. 2. The use according to claim 1, wherein the auxiliary diagnosis is to distinguish patients with acute hepatic failure related to hepatitis e, patients with acute hepatitis e and relatively healthy people.
3. 3. The use according to claim 2, wherein the auxiliary diagnosis comprises detecting the concentration of liver glycogen phosphorylase in the serum of the subject and comparing it with the concentration in acute hepatitis e patient and healthy controls, wherein the concentration of liver glycogen phosphorylase in the serum of the hepatitis e related acute liver failure patient is significantly higher than in the acute hepatitis e patient and healthy controls.
4. 4. The use according to claim 1, wherein the prognostic evaluation comprises predicting the clinical outcome of a patient with hepatitis e associated acute liver failure based on the expression level of serum glycogen phosphorylase.
5. 5. The use according to claim 4, wherein the expression level of serum glycogen phosphorylase is significantly correlated with the number of organ failure in the patient.
6. 6. The use according to claim 4, wherein the dynamic change in the expression level of serum glycogen phosphorylase is associated with the severity of the condition in the patient.
7. 7. The use according to claim 1, characterized in that the biomarker is used for the preparation of a kit for the assisted diagnosis and/or prognosis evaluation of acute liver failure associated with hepatitis e.
8. 8. The use according to claim 7, wherein the kit is a quantitative detection kit, an ELISA diagnostic kit, a colloidal gold kit.
9. 9. The serum glycogen phosphorylase L is used as a biomarker to prepare a product for auxiliary diagnosis and/or prognosis evaluation of acute liver failure related to hepatitis E.
10. 10. The product of claim 9, comprising a kit, a model, and a diagnostic system.

Description

Application of PYGL as auxiliary diagnostic marker for acute liver failure related to hepatitis E Technical Field The invention belongs to the technical field of biomedical detection, and particularly relates to application of PYGL as an auxiliary diagnostic marker for acute liver failure related to hepatitis E. Background Hepatitis E Virus (HEV) is a single-stranded positive sense RNA virus, one of the major causative agents of acute viral hepatitis worldwide. Its genome typically encodes 3 open reading frames, i.e., ORF1, 0RF2 and ORF3. According to the world health organization data, there are about 2000 tens of thousands of infections of hepatitis E each year worldwide, with 340 of the tens of thousands presenting clinical symptoms, resulting in about 7 tens of thousands of deaths and 3000 dead births, imposing a heavy burden on global public health. Hepatitis E virus is transmitted primarily by the faecal-oral route. Currently 8 different genotypes have been identified, of which genotype 1 and genotype 2 only infect humans, and genotype 3 and genotype 4 are zoonotic. Furthermore, studies have reported 1 case of genotype 7 infection by eating contaminated camel meat and milk. Although hepatitis E infection is often manifested as an asymptomatic or self-limiting disease in immunocompromised persons, acute hepatitis may even progress to liver failure, with a high mortality rate, in pregnant women, elderly persons or patients with underlying liver disease. However, current diagnosis of acute liver failure associated with hepatitis E (HEV-ALF) mainly depends on virology detection (anti-HEV antibody, HEV RNA) and comprehensive judgment of traditional liver function indexes and coagulation indexes (such as ALT, AST, TBIL, INR), but the indexes have obvious limitations in early warning of diseases, layering of severe risks and prognosis evaluation, and lack of biomarkers with high sensitivity and high specificity. Glycogen phosphorylase (Glycogen phosphorylase, GP) is a key rate-limiting enzyme in glycogenolysis and catalyzes the production of glucose-1-phosphate, involved in energy supply to the body. Human GP has mainly three tissue-specific subtypes, PYGL (liver type, 97 kDa), PYGM (muscle type, 97 kDa) and PYGB (brain type, 96.6 kDa). Recent studies have shown that GP is involved not only in physiological metabolic regulation, but that its abnormal expression is also associated with disease progression. Among them, the role of liver glycogen Phosphorylase (PYGL) in the development of hepatocellular carcinoma has been attracting attention. Studies have shown that elevated expression of PYGL in hepatocellular carcinoma (HCC) tissue promotes tumor cell proliferation, migration and invasion, and down-regulating PYGL expression inhibits hepatocellular carcinoma progression. Further mechanical researches show that the hepatitis B virus DNA polymerase can enhance glycolysis and promote liver cancer progression by up-regulating PYGL expression and reprogramming Cheng Tang metabolic pathways. Although the role of PYGL in chronic liver diseases such as hepatocellular carcinoma has been studied, its expression level and clinical value in acute liver injury, particularly acute liver failure caused by hepatitis E infection, are not clear. At present, no study report exists on diagnosis and prognosis evaluation of PYGL in acute liver failure related to hepatitis E. Thus, there is a strong need in the art for a novel biomarker that can identify patients with hepatitis E-associated acute liver failure early and specifically, and that can effectively predict disease diagnosis and prognosis. Disclosure of Invention Technical problem The technical problem to be solved by the invention is that an objective and reliable biomarker which can identify an acute liver failure patient related to hepatitis E early and specifically and distinguish the acute liver failure patient from Acute Hepatitis E (AHE) and can effectively predict auxiliary diagnosis and prognosis evaluation of diseases is urgently needed in the field. Technical proposal The present invention provides a biomarker for early assisted diagnosis of hepatitis E associated acute liver failure (HEV-ALF) and distinguishing it from Acute Hepatitis E (AHE), which is serum liver glycogen Phosphorylase (PYGL). The auxiliary diagnosis refers to distinguishing patients with acute hepatic failure related to hepatitis E, acute hepatitis E and relatively healthy people. The first healthy people refer to people without AHE and HEV-ALF. The biomarkers can be used for early and accurate prediction of clinical outcome (such as survival/death) of HEV-ALF patients. The biomarker can dynamically reflect the organ failure quantity and the disease evolution of HEV-ALF patients and is used for risk assessment and disease monitoring. The invention provides application of the biomarker in preparation of products for diagnosing and/or prognosis evaluating acute liver failure related to hepatit